Abstract
Multiple endocrine neoplasia type 1 (MEN 1) is an autosomal dominantly inherited disorder characterized by parathyroid hyperplasia, anterior pituitary adenomas and neoplasms of the endocrine cells of the gastroenteric tract. It has been established that also other tissues exhibit excessive proliferation associated to the MEN 1 syndrome: carcinoids (bronchial and intestinal), lipomas (visceral and cutaneous), thyroid adenomas and goiter, and adrenal gland cortex adenomas. The men1 gene has been mapped by genetic studies to the long arm of human chromosome 11, region q12–13. Genetic analysis of families and tumoral deletion mapping made possible to narrow the men1 region to a 5 cM interval on chromosome 11q12–13. Thirteen marker complexes (17 DNA probes) were found to be linked to the men 1 gene and they span a 14% meiotic recombination with the men 1 locus in the middle. We report a genetic study on 103 subjects from 7 collected MEN 1-kindreds, six Italian and one German, including 30 affected individuals. By linkage analysis to 9 DNA markers (10 DNA probes) of the chromosome region where the men 1 gene maps (11q12–13), we identified 10 mutant gene carriers. The predicted MEN 1 diagnosis was clinically confirmed for 2 of these identified carriers. A predictive accuracy of this genetic test can reach up to 99.5% when it is possible to exclude meiotic crossing-over between the analyzed DNA markers and the disease locus.
Similar content being viewed by others
References
Lips C.J.M., Vasen H.F.A., Lamers C.B.H.W. Multiple Endocrine Neoplasia. CRC Crit. Rev. Oncol. Hematol. 2: 117, 1984.
Duh Q.Y., Hybarger C.P., Geist R., Gamsu G.. Goodman P.C., Gooding G.A.W., Clark O.H. Carcinoid associated with multiple endocrine neoplasia syndromes. Am. J. Surg. 154: 142,1987.
Lamers C.B., Froeling P.G. Clinical significance of hyperparathyroidism in familial multiple endocrine adenomatosis type I (MEA). Am. J. Med. 66: 422,1979.
Marx S.J., Vinik A.I., Santen R.J. Floyd J. C., Mills J.L., Green III J. Multiple endocrine neoplasia type I: assesment of laboratory tests to screen for the gene in a large kindred Medicine 65: 226, 1986.
Oberg F., Walinder O., Bostrom H., Lundqvist G., Wide L. Peptide hormone markers in screening for endocrine tumors in multiple endocrine adenomatosis type 1. Am. J. Med. 73: 619, 1982.
Eberle F., Grun R. Multiple endocrine neoplasia type I (MEN 1). Ergeb Inn. Med. Kinderheilkd 46: 76, 1981.
Croisier J.C., Lehy T., Zeitoun P. A2 cell pancreatic microadenomas in a case of multiple endocrine adenomatosis. Cancer 28: 707, 1971.
Peaurifory J.T., Gomez L.G., Thompson J.S. Separate pancreatic gastrin cell and beta-cell adenomas: report of a patient with multiple endocrine adenomatosis type 1. Archiv. Surg. 114: 956, 1979.
Tiengo A., Fedek D., Marchiori E., Nosadini R., Muggeo M. Suppression and stimulation mechanism controlling glucagon secretion in a case of islet cell tumour producing glucagon, insulin and gastrin. Diabetes 25: 408, 1986.
Long R.G., Bryant M.G., Mitchell S.J., Adrian T.E., Polak J.M., Bloom S.R. Clinopathological study of pancreatic and ganglioneuroblastoma tumour secreting vasoactive intestinal polypeptide (VIPoma). Lancet 2: 764, 1979.
Yamaguchi K., Kameya T., Abe K. Multiple endocrine neoplasia type Clin. I. Endocrinol. Metab. 9: 261,1980.
Kloppel G., Willener S., Stamm B., Hacki W. H., Heitz P.U. Pancreatic lesions and hormonal profile of pancreatic tumors in multiple endocrine neoplasia type 1. An immunocytochemical study of nine patients. Cancer 57: 1824,1986.
Majewski J.T., Wilson S.D. The MEA-syndrome: An all or none phenomenon? Surgery 86:475,1979.
O’Neal L.W., Kipnis D.M., Luse S.A., Lacy P.E., Jarret L. Secretion of various endocrine substances by ACTH-secreting tumors-gastrin, melanotropin, norepinephrine, serotonin, parathormone, vasopressin, glucagon. Cancer 21: 1219, 1968.
Marx S.J., Spiegel A.M., Brown E.M., Aurbach G.D. Family studies in patients with primary parathyroid hyperplasia. Am. J. Med. 62: 698,1977.
Hershon K.S., Kelly W.A., Shaw C.M., Schwartz R., Bierman E.L. Prolactinima as part of the multiple endocrine neoplastic syndrome. Am. J. Med. 74: 713,1983.
Bear J.C., Briones-Urbina R., Fahey J.F., Farid N.R. Variant multiple neoplasia type I (MEN I-Buri): further studies and non-linkage to HLA. Hum. Hered. 35:15,1985.
Farid N.R., Buehler S., Rüssel N.A., Maroun F.B., Allerdice P., Smyth H.S. Prolactinoma in familial multiple endocrine neoplasia type I. Am. J. Med. 69: 874,1980.
Skogseid B., Eriksson B., Lundkvist G., Lorelius L., Rastad J., Wide L., Akerstrom G., Oberg K.J. Multiple endocrine neoplasia type I-A ten ytear prospective screening study in four kindreds. J. Clin. Endocrinol. Metab. 73: 281,1991.
Brandi M.L., Marx S.J., Aurbach J.D., Fitzpatrick L.A. Familial multiple endocrine neoplasia type I: a new look at pathophysiology. Endocr. Rev. 8: 391,1987.
Brandi M.L., Weber G., Svensson A., Falchetti A., Tonelli F., Castello R., Furlani R., Scappaticci S., Fraccaro M. Larsson C. Homozygotes for the autosomal dominant neoplasia syndrome (MEN I). Am. J. Hum. Genet. 53: 1167, 1993.
Kidd K.K., Bowcock A.M., Schmidtke J., Track R.K., Ricciuti F., Hutching G., Bale A., Pearson P. Willard H.F., with help from Gelernter J., Giuffra R., and Kubzdela K. Human gene mapping 10. Cytogenet. Cell. Genet. 51: 622, 1989.
Tokino T., Takahashi E., Mori M., Tanigami A., Glaser T., Park J.W., Jones C., Hori T., Nakamura Y. Isolation and mapping of 62 new RFLP markers on human chromosome 11. Am. J. Hum. Genet. 48: 258,1991.
Tanigami A., Tokino T., Takiguchi S., Mori M., Glaser T., Park J.W., Jones C., Nakamura Y. Mapping of 262 DNA Markers into 24 intervals on human chromosome 11. Am. J. Hum. Genet. 50: 56,1992.
Larsson C., Weber G., Kvanta E., Lewis K., Janson M., Jones C., Glaser T., Evans G., Nordenskjold M. Isolation and mapping of polymorphic cosmid clones used for sublocalization of the multiple endocrine neoplasia type 1 (MEN 1) locus. Hum. Genet. 89: 187, 1992.
Williamson R., Bowcock A., Kidd K., Pearson P., Schmidtke J., Chan H.S., Chipperfield M., Cooper D.N., Hewitt J., Lewitter F., Maidak B., Quitt M., Ricciuti F., Track R. Human gene mapping 10.5. Cytogenet. Cell Genet. 55: 457, 1990.
Nakamura Y., Larsson C., Julier C., Bystrom C., Skogseid B., Wells S., Ober K., Carlon M., Taggart T., O’ Connel P., Leppert M., Lalouel J.M., Nordenskjold M., White R. Localization of the genetic defect in multiple endocrine neoplasia type 1 within a small region of chromosome 11. Am. J. Hum. Genet. 44: 751, 1989.
Julier C., Nakamura Y., Lathrop M., O’ Connel P., Leppert M., Litt M., Mohandas T., Lalouel J.M., White R. Detailed map of the long arm of chromosome 11. Genomics 7: 335,1990.
Janson M., Larsson C., Werelius B., Jones C., Glaser T., Nakamura Y., Jones C.P., Nordenskjold M. Detailed physical map of human chromosomal region 11q12–13 shows high meiotic recombination rate around the MEN 2 locus. Proc. Natl. Acad. Sci. USA 88: 10609, 1991.
Larsson C., Shepherd J., Nakamura Y., Blomberg C., Weber G., Werelius B., Hayward N., Teh B., Tokino T., Seizinger B., Skogseid B., Oberg K., Nordenskjold M. Predictive testing for multiple endocrine neoplasia type 1 using DNA polymorphism. J. Clin. Invest. 89: 1344, 1992.
Larsson C., Skogseid B., Oberg K., Nakamura Y., Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332: 85, 1988.
Friedman E., Sakaguchi K., Bale A.E., Falchetti A., Streeten E., Zimering M., Weinstein L, McBride W., Nakamura Y., Brandi M.L., Norton J.A., Aurbach G.D., Spiegel A., Marx S.J. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. N. Engl. J. Med. 321: 213, 1989.
Falchetti A., Bale A.E., Amorosi A., Bandini S., Cicchi P., Bordi C., Marx S.J., Brandi M.L. Progression of uremic hyperparathyroidism involves allelic loss in the men 1 region on chromosome 11. J. Clin. Endocrinol. Metab. 76: 139,1993.
Thakker R.V., Bouloux P., Wooding C., Chotai K., Broad P.M., Spurr N.K., Besser G.M., O’ Riordan J.L Association of parathyroid tumors in multiple endocrine neoplasia type I with loss of alleles on chromosome 11. N.Engl.J.Med. 321: 218, 1989.
Knudson A.G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 68: 820,1971.
Moffatt M.F. Dinucleotide repeat polymarlphism at the D11S480 locus. Hum. Mol. Genet. 2: 492,1993.
Iwasaki H., Stewart P.W., Dilley W.G., Holt M.S., Steinbrueck T.D., Wells S.A.Jr., Donis-Keller H. A minisatellite and a microsatellite polymorphism within 1.5 kb at the Human Muscle Glycogen phospholylase (PYGM) locus can be amplified by PCR and have combined informativeness of PIC 0.95. Genomics 13: 7, 1992.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morelli, A., Falchetti, A., Castello, R. et al. Genetic screening to identify the gene carrier in Italian and German kindreds affected by multiple endocrine neoplasia type 1 (MEN 1) syndrome. J Endocrinol Invest 18, 329–335 (1995). https://doi.org/10.1007/BF03347833
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03347833